Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(03): 156-162
DOI: 10.1055/s-0042-110570
Article
© Georg Thieme Verlag KG Stuttgart · New York

The Effect of Coenzyme Q10 Supplementation on Circulating Levels of Novel Adipokine Adipolin/CTRP12 in Overweight and Obese Patients with Type 2 Diabetes

P. Mehrdadi
1   Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
,
R. Kolahdouz Mohammadi
1   Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
,
E. Alipoor
1   Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
,
M. R. Eshraghian
2   Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
,
A. Esteghamati
3   Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
,
M. J. Hosseinzadeh-Attar
1   Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
› Author Affiliations
Further Information

Publication History

received 18 May 2016
first decision 10 June 2016

accepted 16 June 2016

Publication Date:
22 September 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Adipolin, the novel adipokine that is proposed to be reduced in diabetes, obesity and inflammation, may improve glycemic control. It is known that coenzyme Q10 could improve insulin sensitivity. The aim of the current study was to investigate the effect of Q10 supplementation on adipolin concentration and glucose metabolism in overweight and obese diabetic patients.

Material & Methods: Sixty four patients with type 2 diabetes and 25<BMI<35 kg/m2 were randomly divided to receive 200 mg Q10 or placebo daily for 12 weeks. Fasting serum levels of adipolin, glucose, insulin, HbA1c and HOMA-IR were measured before and after supplementation.

Results: Following supplementation, adipolin levels decreased significantly in Q10 group (38.19±32.02 to 29.03±34.23 ng/ml;P=0.001). HbA1c decreased dramatically following supplementation only in Q10 group (8.6±2.2% to 7.9±2.1%, P<0.001). It was also marginally lower in Q10 compared to placebo group at the end of study (P=0.056). Moreover, weight (P=0.003), BMI (P=0.003) and waist circumference (P=0.016) decreased significantly in Q10 group. No significant alterations were observed in FBS, fasting insulin and HOMA-IR within or between Q10 and placebo groups.

Conclusions: Coenzyme Q10 reduced HbA1c considerably in overweight and obese patients with diabetes, although interestingly adipolin levels declined simultaneously. In this study, Q10 modulated glucose homeostasis, which was expected to be mediated by increasing adipolin. The similar mechanisms of action of Q10 and adipolin may justify lowering effect of Q10 on adipolin. In addition, the possible anti-adipogenic effect of Q10 might explain the significant reduction in weight and waist circumference and hence the adipolin decrease. Further studies are required to evaluate the precise role of adipolin in glucose metabolism as well as the probable effects of coenzyme Q10 on adipose tissue and adipokines.

Key words

coenzyme Q10 - adipolin - type 2 diabetes - obesity
 

  • References

  • 1 Enomoto T, Ohashi K, Shibata R et al. Adipolin/C1qdc2/CTRP12 protein functions as an adipokine that improves glucose metabolism. J Biol Chem 2011; 286: 34552-34558
    CrossrefPubMedGoogle Scholar
  • 2 Wei Z, Peterson JM, Lei X et al. C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes. J Biol Chem 2012; 287: 10301-10315
    CrossrefPubMedGoogle Scholar
  • 3 Enomoto T, Shibata R, Ohashi K et al. Regulation of adipolin/CTRP12 cleavage by obesity. Biochem Biophys Res Commun 2012; 428: 155-159
    CrossrefPubMedGoogle Scholar
  • 4 Hodgson J, Watts G, Playford D. Original Communication-Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56: 1137-1142
    CrossrefPubMedGoogle Scholar
  • 5 Eriksson J, Forsen T, Mortensen S et al. The effect of coenzyme Q~ 1~ 0 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors-Oxford Then Amsterdam 1999; 9: 315-318
    PubMedGoogle Scholar
  • 6 Sena CM, Nunes E, Gomes A et al. Supplementation of coenzyme Q 10 and α-tocopherol lowers glycated hemoglobin level and lipid peroxidation in pancreas of diabetic rats. Nutrition research 2008; 28: 113-121
    CrossrefPubMedGoogle Scholar
  • 7 Kolahdouz MR, Hosseinzadeh-Attar M, Eshraghian M et al. The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients. Minerva Gastroenterol Dietol 2013; 59: 231-236
    PubMedGoogle Scholar
  • 8 Hernández-Ojeda J, Cardona-Muñoz EG, Román-Pintos LM et al. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications 2012; 26: 352-358
    CrossrefPubMedGoogle Scholar
  • 9 Singh RB, Niaz MA, Rastogi SS et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999; 13: 203-208
    CrossrefPubMedGoogle Scholar
  • 10 Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdon) 2014; 42: 698-702 DOI: 10.1016/j.mpmed.2014.09.007.
    CrossrefPubMedGoogle Scholar
  • 11 Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254-1264 DOI: 10.2522/ptj.20080020.
    CrossrefPubMedGoogle Scholar
  • 12 Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World journal of diabetes 2015; 6: 456-480 DOI: 10.4239/wjd.v6.i3.456.
    CrossrefPubMedGoogle Scholar
  • 13 Tan BK, Chen J, Adya R et al. Metformin increases the novel adipokine adipolin/CTRP12: role of the AMPK pathway. J Endocrinol 2013; 219: 101-108
    CrossrefPubMedGoogle Scholar
  • 14 Tan BK, Chen J, Hu J et al. Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. Clin Endocrinol (Oxf) 2014; 81: 841-846
    CrossrefPubMedGoogle Scholar
  • 15 Tan BK, Lewandowski KC, O’Hare JP et al. Insulin regulates the novel adipokine adipolin/CTRP12: in vivo and ex vivo effects. J Endocrinol 2014; 221: 111-119
    CrossrefPubMedGoogle Scholar
  • 16 Amin MM, Asaad GF, Salam RMA et al. Novel CoQ10 antidiabetic mechanisms underlie its positive effect: modulation of insulin and adiponectine receptors, tyrosine kinase, PI3K, glucose transporters, sRAGE and visfatin in insulin resistant/diabetic rats. PloS one 2014; 9
    PubMedGoogle Scholar
  • 17 Lee SK, Lee JO, Kim JH et al. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARalpha induction in 3T3-L1 preadipocytes. Cell Signal 2012; 24: 2329-2336 DOI: 10.1016/j.cellsig.2012.07.022.
    CrossrefPubMedGoogle Scholar
  • 18 Choi Y, Kim Y, Ham H et al. Nobiletin suppresses adipogenesis by regulating the expression of adipogenic transcription factors and the activation of AMP-activated protein kinase (AMPK). J Agric Food Chem 2011; 59: 12843-12849 DOI: 10.1021/jf2033208.
    CrossrefPubMedGoogle Scholar
  • 19 Vingtdeux V, Chandakkar P, Zhao H et al. Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 2011; 17: 1022-1030 DOI: 10.2119/molmed.2011.00163.
    CrossrefPubMedGoogle Scholar
  • 20 Hodgson JM, Watts GF, Playford DA et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56: 1137-1142 DOI: 10.1038/sj.ejcn.1601464.
    CrossrefPubMedGoogle Scholar
  • 21 International Expert C. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334 DOI: 10.2337/dc09-9033.
    CrossrefPubMedGoogle Scholar
  • 22 Zahedi H, Eghtesadi S, Seifirad S et al. Effects of CoQ10 supplementation on lipid profiles and glycemic control in patients with type 2 diabetes: a randomized, double blind, placebo-controlled trial. Journal of Diabetes & Metabolic Disorders 2014; 13: 1-8
    CrossrefPubMedGoogle Scholar
  • 23 Mezawa M, Takemoto M, Onishi S et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors 2012; 38: 416-421
    CrossrefPubMedGoogle Scholar
  • 24 Pfützner A, Kunt T, Hohberg C et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004; 27: 682-687
    CrossrefPubMedGoogle Scholar
  • 25 Anderson RA, Evans ML, Ellis GR et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001; 154: 475-483
    CrossrefPubMedGoogle Scholar
  • 26 Wei Z, Lei X, Seldin MM et al. Endopeptidase cleavage generates a functionally distinct isoform of C1q/tumor necrosis factor-related protein-12 (CTRP12) with an altered oligomeric state and signaling specificity. J Biol Chem 2012; 287: 35804-35814
    CrossrefPubMedGoogle Scholar